Dr. John K. Cini Ph.D. Net Worth

Dr. John K. Cini Ph.D. biography

Dr. John K. Cini Ph.D. is the Chief Scientific Officer & Co-Founder at Sonnet BioTherapeutics Inc.

What is the salary of Dr D?

As the Chief Scientific Officer & Co-Founder of Sonnet BioTherapeutics Inc, the total compensation of Dr D at Sonnet BioTherapeutics Inc is $302,923. There are 3 executives at Sonnet BioTherapeutics Inc getting paid more, with Dr. Pankaj Mohan Ph.D. having the highest compensation of $792,166.

How old is Dr D?

Dr D is 68, he's been the Chief Scientific Officer & Co-Founder of Sonnet BioTherapeutics Inc since . There are no older and 6 younger executives at Sonnet BioTherapeutics Inc.

What's Dr D's mailing address?

John's mailing address filed with the SEC is 100 OVERLOOK CENTER, SUITE 102, , PRINCETON,, NJ, 08540.

Insiders trading at Sonnet BioTherapeutics Inc

Over the last 8 years, insiders at Sonnet BioTherapeutics Inc have traded over $53,380 worth of Sonnet BioTherapeutics Inc stock and bought 641,484 units worth $290,512 . The most active insiders traders include Pankaj Mohan, Donald J. Griffith y Michael D Pruitt. On average, Sonnet BioTherapeutics Inc executives and independent directors trade stock every 86 days with the average trade being worth of $21,474. The most recent stock trade was executed by Raghu Rao on 27 October 2023, trading 15,625 units of SONN stock currently worth $12,739.

What does Sonnet BioTherapeutics Inc do?

sonnet biotherapeutics is an early stage company developing a pipeline of bifunctional therapies that attack immune-modulating targets to control cancer cells. sonnet biotherapeutics is utilizing a platform approach to develop a library of cancer-fighting immunotherapies. sonnet is based in cranbury, new jersey. sonnet mission: sonnet biotherapeutics is a platform enabled proof-of-concept engine created to generate immuno-oncology candidates and develop them into phase ii assets. we are leveraging a unique ip driven platform: ● single chain platform with pk enhancement ● selectively targeting tumors and their micro-environment ● validated targets only ● dual targeting can create synergies

Sonnet BioTherapeutics Inc executives and stock owners

Sonnet BioTherapeutics Inc executives and other stock owners filed with the SEC include:

• Dr. Pankaj Mohan Ph.D.,
  Founder, Chairman. CEO & Pres
• Dr. Pankaj Mohan,
  Founder, Chairman. CEO & Pres
• Jay Cross,
  Chief Financial Officer
• Dr. John K. Cini Ph.D.,
  Chief Scientific Officer & Co-Founder
• Dr. Richard T. Kenney FACP, M.D.,
  Chief Medical Officer
• Manuel Dafonseca,
  Head of Clinical Operations
• Dr. Richard T. Kenney,
  Chief Medical Officer
• Susan Dexter,
  Chief Technical Officer
• Frederick L Glick,
  President
• Albert D. Dyrness,
  Director
• Lori Mc Neill,
  Director
• Gregory Evan Kraut,
  Director
• Larry Spitcaufsky,
  
• Richard Adams,
  
• Neil G Kiefer,
  Director
• Russell Jacob Page,
  Director
• Keith J Johnson,
  Director
• Troy Matson Shadoin,
  Chief Accounting Officer
• Patrick Clay Harkleroad,
  Chief Financial Officer
• Michael D Pruitt,
  CEO, Chairman
• J Eric Wagoner,
  Director
• John K. Cini,
  Chief Scientific Officer
• Donald J. Griffith,
  Director
• Susan Dexter,
  Chief Technical Officer
• John Harry Iii Cross,
  Chief Financial Officer
• Nailesh Bhatt,
  Director
• Pankaj Mohan,
  Chairman, President and CEO
• Terence Anthony Rugg,
  Chief Medical Officer
• Raghu Rao,
  Director
• Richard T Kenney,
  Chief Medical Officer